ImmuCell (NASDAQ:ICCC) Share Price Crosses Above 200 Day Moving Average - Time to Sell?

Key Points

• ImmuCell shares crossed above their 200-day moving average, reaching $10.02 before last trading at $9.84, compared with a 200-day average of $8.96.
• The company reported better-than-expected quarterly results, posting EPS of $0.20 versus a $0.05 estimate and revenue of $7.19 million versus the $5.40 million consensus.
• Analyst sentiment remains cautious: despite one “strong-buy” upgrade, the overall consensus rating is Hold. ImmuCell has a $89.35 million market capitalization and a high price-to-earnings ratio of 123.02.

ImmuCell Corporation (NASDAQ:ICCC - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $8.96 and traded as high as $10.02. ImmuCell shares last traded at $9.84, with a volume of 15,550 shares.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Wall Street Zen raised ImmuCell to a "strong-buy" rating in a report on Saturday, June 27th. Weiss Ratings raised ImmuCell from a "sell (d-)" rating to a "hold (c-)" rating in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Hold".

ImmuCell Stock Down 0.6%

The firm has a market capitalization of $89.35 million, a price-to-earnings ratio of 123.02 and a beta of 0.54. The stock has a fifty day moving average of $10.59 and a two-hundred day moving average of $8.96. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.75 and a quick ratio of 2.71.

ImmuCell (NASDAQ:ICCC - Get Free Report) last announced its earnings results on Thursday, August 13th. The biotechnology company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.05 by $0.15. The firm had revenue of $7.19 million for the quarter, compared to the consensus estimate of $5.40 million. ImmuCell had a return on equity of 2.69% and a net margin of 2.57%.

Insider Activity at ImmuCell

In related news, CEO Boekhorst Paul Francis Oliv Te bought 8,000 shares of ImmuCell stock in a transaction that occurred on Thursday, June 18th. The shares were acquired at an average cost of $9.49 per share, for a total transaction of $75,920.00. Following the completion of the acquisition, the chief executive officer directly owned 17,785 shares of the company's stock, valued at approximately $168,779.65. The trade was a 81.76% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 5.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Militia Capital Management LLC bought a new position in ImmuCell during the first quarter worth $114,000. Dimensional Fund Advisors LP lifted its holdings in ImmuCell by 3.2% in the first quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company's stock valued at $355,000 after buying an additional 1,749 shares during the period. Geode Capital Management LLC grew its holdings in ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock worth $500,000 after acquiring an additional 2,907 shares during the period. Finally, Mesirow Financial Investment Management Inc. grew its holdings in ImmuCell by 199.6% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company's stock worth $224,000 after acquiring an additional 24,303 shares during the period. Institutional investors own 13.47% of the company's stock.

ImmuCell Company Profile

ImmuCell Corporation NASDAQ: ICCC is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company's flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.